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CLINICAL PRIOR AUTHORIZATION PROGRAM: A STRATEGY
FOR CONTROLLING DRUG EXPENDITURES AMONG
PATIENTS WITH INSOMNIA
Sun SX, McMurray J, Jacobsen V, Fuldeore M, Lee K, Bertram C
Walgreens Health Initiatives, Deerﬁeld, IL, USA
OBJECTIVE: Insomnia Clinical Prior Authorization (CPA)
program is designed to ensure appropriate utilization of insom-
nia medications and does not allow for chronic use unless
medical condition or medication is causing insomnia. The
purpose of this study was to evaluate the impact of the program
on the utilization and expenditures of insomnia medications.
METHODS: Using a retrospective pre-post with control group
study design, prescription records from January 1, 2003 to
October 31, 2004 were obtained from Walgreens Health Initia-
tives’ pharmacy claims database. The study group comprised of
166,719 eligible lives from three employer groups enrolled in 
the Insomnia CPA program, and the control group comprised 
of 501,779 eligible lives from 150 clients not enrolled in this
program. The number of prescriptions dispensed and the total
costs per member per month (PMPM) were analyzed for the two
groups in the pre and post period. PMPM cost savings (Y’) were
calculated using the following formula: Y¢ = Yst0*Rct - Yst1, where
Yst0 and Yst1 represent actual pre and post PMPM total costs in
the study group and Rct is the ratio of PMPM pre and post total
costs in the control group. RESULTS: From the pre to post
period, in the study group, the average number of prescriptions
per month increased by 8.5%, while the average PMPM costs
decreased by 8.4% (from $0.42 to $0.39). In the control group,
the average number of prescriptions per month as well as the
average PMPM costs increased by 63.3% and 42.9% respec-
tively. After comparing the trend among insomnia products in
these two groups, it was estimated that WHI’s Insomnia CPA
program resulted in $0.21 PMPM and total of $420,132 annu-
alized cost savings for the three employer groups. CONCLU-
SIONS: Clinical prior authorization program is effective in
controlling drug expenditures for patients with insomnia.
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PHYSICIAN AND PATIENT DETERMINANTS OF THE
TREATMENT OF SLEEP DIFFICULTIES IN OUTPATIENT
SETTINGS IN THE UNITED STATES
Rasu R1, Balkrishnan R2, Rajagopalan R3
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2Ohio State University, Columbus, OH, USA; 3Takeda Pharmaceuticals
North America, Lincolnshire, IL, USA
OBJECTIVE: This study analyzed socioeconomic and clinical
factors relating to both physicians and patients associated with
physicians’ choice of the treatment for sleep difﬁculties in a
nationally representative sample of outpatient physician visits in
the US. METHODS: A modiﬁed version of the model suggested
by Eisenberg was used as a theoretical framework for this study
to predict the factors inﬂuencing treatment of sleep difﬁculties.
A multivariate logistic regression method was used to analyze
the 1996–2001 National Ambulatory Medical Care Survey data
to examine physician and patient related predictors of treatment
variations for sleep difﬁculties RESULTS: From 1996 to 2001,
about 4.8 billion visits were made to outpatient physician ofﬁces
in the US, and 94.6 million of these were sleep-difﬁculty related
visits. This study found that 32% of patients with sleep difﬁcul-
ties received no type of therapy during their visits and 5% of the
patients received behavioral therapy only. Psychiatrist visits were
72% more likely (OR: 1.72, 95% CI: 1.08–2.61) to be associ-
ated with receipt of medication therapy and ten times more likely
(OR: 10.19, 95% CI: 4.85–14.44) to be associated with behav-
ioral therapy prescription only than visits to family practitioners
and internists. Patient visits with public insurance as a primary
payer source were more likely to be associated with benzodi-
azepine prescription among patients receiving at least some 
medication therapy (OR: 1.66, 95% CI: 1.13–2.45) than patient
visits with private insurance as a primary payer source. CON-
CLUSIONS: The results of this study indicate that several patient
and physician characteristics inﬂuence physician prescribing of
treatments for sleep difﬁculties. This study suggests a need to
develop better care management guidelines for sleep difﬁculties
and a wider coverage of behavioral therapy in the US. The study
also ﬁnds variations in quality of care and treatment for sleep
difﬁculties in outpatient settings in the US.
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SLEEP COMPLAINTS AND DIAGNOSES IN THE NATIONAL
AMBULATORY MEDICAL CARE SURVEY: 1997–2002
Tan LSM, Morlock R
Pifzer Inc, Ann Arbor, MI, USA
OBJECTIVES: Insomnia symptoms have been reported to
impact the lives of approximately 83 million people of the United
States general population. However, insomnia complaints are
often underreported and underdiagnosed. This study describes
patient characteristics of those who do and do not present with
insomnia complaints in the National Ambulatory Medical Care
Survey (NAMCS). METHODS: Data was obtained from the 6
years of NAMCS data (1997 through 2002). Descriptive analy-
ses were utilized to examine individuals who listed insomnia as
one of three possible reasons for their ofﬁce visit relative to those
who did not have an insomnia complaint. Patient level weights
were utilized to derive US national population estimates. Given
the complex stratiﬁed survey design, Rao Scott and Wald Chi-
square tests were used to assess statistically signiﬁcant differences
within groups. RESULTS: Patients reported an insomnia com-
plaint as the reason for their visit in only 0.6% of all visits. The
majority of these patients (64%) were treated by primary care
specialists. Across all age groups, approximately twice as many
women as men presented with a complaint of insomnia.
However, a greater percentage of males under the age of 18 years
presented with an insomnia complaint compared to females in
the same age category, 18.3% compared to 11.2%, respectively.
While primary organic diagnoses (55.4%) were the most
common, an insomnia diagnosis occurred in 10.4% of patients
and a diagnosis of depression/anxiety occurred in 27.1% of
patients who listed insomnia as a reason for their visit. CON-
CLUSION: At any point in time insomnia complaints are known
to impact a signiﬁcant portion of the US population, yet, in only
0.6% visits do patients list insomnia as a reason for their visit.
This study provides an important descriptive look at those who
do and do not present with a complaint of insomnia.
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SEDATIVE HYPNOTICS EMPLOYED TO TREAT PATIENTS WITH
AND WITHOUT INSOMNIA COMPLAINTS IN THE NATIONAL
AMBULATORY MEDICAL CARE SURVEY: 1997–2002
Tan LSM, Morlock R
Pifzer Inc, Ann Arbor, MI, USA
OBJECTIVES: Pharmaceutical treatments are available for
patients with a complaint of insomnia. These treatments often
vary by patient and physician characteristics. This study
describes the use of several medications commonly used to treat
sleep disorders as reported in the National Ambulatory Medical
Care Survey (NAMCS). METHODS: Data was obtained from
the six years of NAMCS data (1997 through 2002). Analyses
were utilized to examine medications (ie., triazolam, temazepam,
